ID

27361

Beskrivning

Study ID: 103094 Clinical Study ID: ARI103094 Study Title: ARI103094-Follow-Up Study for REDUCE Study Subjects Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00883909 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: dutasteride Trade Name: Zytefor,Zyfetor,Duagen,Avolve,Avodart,Avidart Study Indication: Neoplasms, Prostate CRF Seiten: 934-977

Nyckelord

Versioner (3)
  1. 2017-11-09 2017-11-09 -
  2. 2017-11-09 2017-11-09 -
  3. 2017-11-26 2017-11-26 -
Rättsinnehavare

GlaxoSmithKline

Uppladdad den

9 november 2017

DOI

För en begäran logga in.

Licens

Creative Commons BY-NC 3.0
Modellkommentarer :

Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.

Tillbaka till modellkommentarer
Itemgroup-kommentar för :

Item-kommentar för :

Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.

Screen visit GSK study Prostatic neoplasms NCT00883909

Engelsk

Screen visit GSK study Prostatic neoplasms NCT00883909

1 Formulär  
Administrative data
Beskrivning

Administrative data

Session number
Beskrivning

Session number

Datatyp

integer

Subject number
Beskrivning

Subject number

Datatyp

text

Previous Subject number
Beskrivning

Previous Subject number

Date of assessment
Beskrivning

Date of assessment

Datatyp

date

Previous Subject Number from the REDUCE (ARI40006) Study
Beskrivning

Previous Subject Number

Datatyp

text

Inclusion / Exclusion Criteria Worksheet
Beskrivning

Inclusion / Exclusion Criteria Worksheet

Inclusion criteria: 1. Has the subject signed and dated a written informed consent?
Beskrivning

If the INCLUSION CRITERIA question is answered NO, this subject must NOT enter this study.

Datatyp

text

Inclusion criteria: 2. Did the subject participate in the REDUCE Study and meet the eligibility criteria for Part A, the 2 Year Observational Follow-Up Study and/or Part B, the Prostate Biopsy Tissue Study?
Beskrivning

If the INCLUSION CRITERIA question is answered NO, this subject must NOT enter this study.

Datatyp

text

Exclusion criteria (Part A only): 1. Is the subject unable/unwilling to participate in the Follow-Up Study telephone calls?
Beskrivning

If any EXCLUSION CRITERIA question is answered YES, this subject must NOT enter this study.

Datatyp

text

Inclusion/Exclusion Criteria
Beskrivning

Inclusion/Exclusion Criteria

Did the subject meet all entry criteria (i.e., All "YES" answers for inclusion criteria, all "NO" answers for exclusion criteria)?
Beskrivning

See INCLUSION / EXCLUSION CRITERIA WORKSHEET.

Datatyp

text

Check all boxes that represent a violation of the inclusion / exclusion criteria: Inclusion criteria 1.
Beskrivning

informed consent violation

Datatyp

boolean

Check all boxes that represent a violation of the inclusion / exclusion criteria: Inclusion criteria 2.
Beskrivning

eligibility criteria violation

Datatyp

boolean

Check all boxes that represent a violation of the inclusion / exclusion criteria: Exclusion criteria 1.
Beskrivning

participation in Follow-Up Study telephone calls violation

Datatyp

boolean

Eligibility Criteria
Beskrivning

Eligibility Criteria

1. Part A: Any subject who has participated in the REDUCE Study and meets one of the following eligibility criteria for Part A, 2 Year Observational Follow-Up Study.
Beskrivning

eligibility part A

Datatyp

boolean

If Part A is checked, indicate which one of the following Part A Eligibility Criteria the subject meets:
Beskrivning

Part A Eligibility Criteria

Datatyp

text

2. Part B: Any subject who was diagnosed with prostate cancer based on a prostate biopsy during participation in the REDUCE Study, regardless of when their REDUCE study participation ended.
Beskrivning

eligibility part B

Datatyp

boolean

Investigator’s Statement
Beskrivning

Investigator’s Statement

Date
Beskrivning

Sign and date this page after all relevant Screening CRF pages, including outstanding test results, are completed. Check that the date of signature is on or after the completion of the Screening Visit.

Datatyp

date

Investigator’s Signature
Beskrivning

Sign and date this page after all relevant Screening CRF pages, including outstanding test results, are completed. "I confirm that I have carefully examined all entries on the Screening Case Report Form for this subject. All information entered by myself or my colleagues is, to the best of my knowledge, correct as of the date."

Datatyp

text

Investigator’s Name - Print
Beskrivning

Investigator’s Name

Datatyp

text

Tillbaka till toppen

Similar models

Screen visit GSK study Prostatic neoplasms NCT00883909

1 Formulär
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Item Group
Administrative data
Session number
Item
Session number
integer
Subject number
Item
Subject number
text
Item Group
Previous Subject number
Date of assessment
Item
Date of assessment
date
Previous Subject Number
Item
Previous Subject Number from the REDUCE (ARI40006) Study
text
Item Group
Inclusion / Exclusion Criteria Worksheet
Item
Inclusion criteria: 1. Has the subject signed and dated a written informed consent?
text
informed consent
Code List
Inclusion criteria: 1. Has the subject signed and dated a written informed consent?
CL Item
Yes (Y)
CL Item
No (N)
Item
Inclusion criteria: 2. Did the subject participate in the REDUCE Study and meet the eligibility criteria for Part A, the 2 Year Observational Follow-Up Study and/or Part B, the Prostate Biopsy Tissue Study?
text
informed consent
Code List
Inclusion criteria: 2. Did the subject participate in the REDUCE Study and meet the eligibility criteria for Part A, the 2 Year Observational Follow-Up Study and/or Part B, the Prostate Biopsy Tissue Study?
CL Item
Yes (Y)
CL Item
No (N)
Item
Exclusion criteria (Part A only): 1. Is the subject unable/unwilling to participate in the Follow-Up Study telephone calls?
text
informed consent
Code List
Exclusion criteria (Part A only): 1. Is the subject unable/unwilling to participate in the Follow-Up Study telephone calls?
CL Item
Yes (Y)
CL Item
No (N)
Item Group
Inclusion/Exclusion Criteria
Item
Did the subject meet all entry criteria (i.e., All "YES" answers for inclusion criteria, all "NO" answers for exclusion criteria)?
text
informed consent
Code List
Did the subject meet all entry criteria (i.e., All "YES" answers for inclusion criteria, all "NO" answers for exclusion criteria)?
CL Item
Yes (Y)
CL Item
No (N)
informed consent violation
Item
Check all boxes that represent a violation of the inclusion / exclusion criteria: Inclusion criteria 1.
boolean
eligibility criteria violation
Item
Check all boxes that represent a violation of the inclusion / exclusion criteria: Inclusion criteria 2.
boolean
participation in Follow-Up Study telephone calls violation
Item
Check all boxes that represent a violation of the inclusion / exclusion criteria: Exclusion criteria 1.
boolean
Item Group
Eligibility Criteria
eligibility part A
Item
1. Part A: Any subject who has participated in the REDUCE Study and meets one of the following eligibility criteria for Part A, 2 Year Observational Follow-Up Study.
boolean
Item
If Part A is checked, indicate which one of the following Part A Eligibility Criteria the subject meets:
text
Part A Eligibility Criteria
Code List
If Part A is checked, indicate which one of the following Part A Eligibility Criteria the subject meets:
CL Item
Completed 4 years on Investigational Product through the REDUCE 4-Year Study Visit (Visit 10). (a)
CL Item
Was diagnosed with prostate cancer during the REDUCE study, discontinued Investigational Product but participated in REDUCE prostate cancer follow-up visits through the 4-Year Study Visit (Visit 10P). (b)
CL Item
Withdrew from REDUCE study visit participation and Investigational Product (for any reasons) but participated in REDUCE follow-up phone calls every 6 months through the 4 Year Phone Call. (c)
eligibility part B
Item
2. Part B: Any subject who was diagnosed with prostate cancer based on a prostate biopsy during participation in the REDUCE Study, regardless of when their REDUCE study participation ended.
boolean
Item Group
Investigator’s Statement
Date
Item
Date
date
Investigator’s Signature
Item
Investigator’s Signature
text
Investigator’s Name
Item
Investigator’s Name - Print
text
Tillbaka till toppen 

Kontakt

Använd detta formulär för feedback, frågor och förslag på förbättringar.

Fält markerade med * är obligatoriska.

Hjälp

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial